# Quantum Biosystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/quantum-biosystems

- Industry: Biotechnology
- Headquarters: Osaka, Japan
- Website: www.quantumbiosystems.com
- Total disclosed funding: $26M
- Latest round: Series B (Feb 6, 2015)
- Investors on record: 5

## About

Quantum Biosystems focuses on developing advanced biosystems technology that addresses critical challenges in healthcare and environmental monitoring, offering innovative products for the life sciences sector.Founded in 2013 in Osaka, Japan, Quantum Biosystems specializes in biosystems technology. The company has executed 5 deals, with its most recent transaction occurring on April 18, 2022. In this round, Quantum Biosystems raised JPY 1000.00 mn from SBI Investment, bringing the total amount raised to JPY 1000.00 mn.Quantum Biosystems specializes in advanced biosystems technology, focusing on the development and commercialization of innovative products designed for various applications in the life sciences sector. Their core product offerings include high-performance biosensors, diagnostic tools, and analytical instruments that facilitate real-time monitoring and analysis of biological samples. These products aim to solve critical challenges in healthcare, environmental monitoring, and research, providing end users with efficient and reliable data to support decision-making. The company's clientele includes research institutions, hospitals, and laboratories, primarily in North America, Europe, and parts of Asia, where they cater to a growing need for precision and accuracy in biological analysis. Released in stages over the last few years, these products have been instrumental in advancing research methodologies and improving diagnostic capabilities across multiple disciplines.The revenue model of Quantum Biosystems is structured around direct sales and strategic partnerships, enabling the company to effectively monetize its innovative products. Transactions typically occur through direct sales to research institutions and healthcare facilities, as well as subscription-based services for ongoing software and product support. The company offers various pricing plans that cater to different client needs, with flagship products commanding premium pricing due to their advanced features and reliability. This structure enhances customer retention and upselling opportunities, fostering long-term relationships with clients who require continuous access to cutting-edge biosystems technology. By focusing on both B2B sales and direct consumer engagement, Quantum Biosystems is positioned to capitalize on its expertise in biosystems technology, driving sustained revenue growth while addressing the evolving needs of its diverse customer base.As of April 2022, Quantum Biosystems has discontinued its operations, indicating a significant shift in its business strategy. The company is no longer pursuing the development of new products or expansion into new markets.

## Funding rounds

- Series B, Feb 6, 2015, $20M — University of Tokyo Edge Capital Partners, JAFCO Group, INCJ, Mitsubishi UFJ Capital, Mizuho Capital
- Series A, Feb 20, 2014, $4.4M — University of Tokyo Edge Capital Partners, JAFCO Group, Mizuho Capital
- Seed, Apr 30, 2013, $1.3M — JAFCO Group

## Investors

- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Seed, Series A, Series B
- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series A, Series B
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series A, Series B
- INCJ — Series B
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series B